TargImmune successfully closed its 2021 financing round
27.07.2021
TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...
News
Monte Rosa Therapeutics raises USD 222 million in successful IPO
29.06.2021
Monte Rosa Therapeutics, a US-Swiss biotech company focused on discovering and developing precision medicines that degrade disease-causing proteins, reached...
Alentis Therapeutics Raises USD 67 Million in Series B Financing
15.06.2021
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.
Virtual Auditorium Talk: ‘How to attract and retain best talents for Life Sciences startups’
14.06.2021
The Technologiepark Basel and the Swiss Biotech Association invite you to a virtual talk about: ‘How to attract and retain best talents for Life Sciences startups’.
BIOVERSYS receives CARB-X Award of up to US$ 15.34 Mio.
02.06.2021
CARB-X funds BioVersys up to US$ 15.34 million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics, targeting difficult to treat ESKAPE pathogens
CARB-X funds BioVersys up to US$ 15.34 million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics, targeting difficult to treat ESKAPE pathogens